Bright Minds Biosciences Inc. DRUG
We take great care to ensure that the data presented and summarized in this overview for BRIGHT MINDS BIOSCIENCES INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in DRUG
Top Purchases
Top Sells
About DRUG
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Insider Transactions at DRUG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
184,331
+14.82%
|
$3,870,951
$21.7 P/Share
|
|
Oct 16
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
50,000
+1.85%
|
$1,200,000
$24.15 P/Share
|
|
Oct 15
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
372,591
+5.26%
|
$2,980,728
$8.29 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 607K shares |
|---|